| Drug repurposing from the perspective of pharmaceutical companies Y Cha, T Erez, IJ Reynolds, D Kumar, J Ross, G Koytiger, R Kusko, ... British journal of pharmacology 175 (2), 168-180, 2018 | 373 | 2018 |
| Transparency and reproducibility in artificial intelligence B Haibe-Kains, GA Adam, A Hosny, F Khodakarami, ... Nature 586 (7829), E14-E16, 2020 | 333 | 2020 |
| Reporting guidelines for human microbiome research: the STORMS checklist C Mirzayi, A Renson, Genomic Standards Consortium, ... Nature medicine 27 (11), 1885-1892, 2021 | 195 | 2021 |
| Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology IW Deveson, B Gong, K Lai, JS LoCoco, TA Richmond, J Schageman, ... Nature biotechnology 39 (9), 1115-1128, 2021 | 148 | 2021 |
| The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease D Ryskamp, J Wu, M Geva, R Kusko, I Grossman, M Hayden, ... Neurobiology of disease 97, 46-59, 2017 | 123 | 2017 |
| Integrated genomics reveals convergent transcriptomic networks underlying chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis RL Kusko, JF Brothers, J Tedrow, K Pandit, L Huleihel, C Perdomo, G Liu, ... American journal of respiratory and critical care medicine 194 (8), 948-960, 2016 | 118 | 2016 |
| Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly (ADP-ribose) polymerase inhibitors X Huang, EA Motea, ZR Moore, J Yao, Y Dong, G Chakrabarti, JA Kilgore, ... Cancer cell 30 (6), 940-952, 2016 | 113 | 2016 |
| Pridopidine activates neuroprotective pathways impaired in Huntington Disease M Geva, R Kusko, H Soares, KD Fowler, T Birnberg, S Barash, ... Human molecular genetics 25 (18), 3975-3987, 2016 | 105 | 2016 |
| Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19) J Kim, J Zhang, Y Cha, S Kolitz, J Funt, R Escalante Chong, S Barrett, ... Journal of translational medicine 18, 1-9, 2020 | 83 | 2020 |
| Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing W Xiao, L Ren, Z Chen, LT Fang, Y Zhao, J Lack, M Guan, B Zhu, ... Nature biotechnology 39 (9), 1141-1150, 2021 | 77 | 2021 |
| PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC K Krysan, R Kusko, T Grogan, J O'Hearn, KL Reckamp, TC Walser, ... Molecular Cancer Research 12 (5), 765-774, 2014 | 69 | 2014 |
| Similarities and differences between variants called with human reference genome HG19 or HG38 B Pan, R Kusko, W Xiao, Y Zheng, Z Liu, C Xiao, S Sakkiah, W Guo, ... BMC bioinformatics 20, 17-29, 2019 | 68 | 2019 |
| Quantitative structure–activity relationship models for predicting inflammatory potential of metal oxide nanoparticles Y Huang, X Li, S Xu, H Zheng, L Zhang, J Chen, H Hong, R Kusko, R Li Environmental health perspectives 128 (6), 067010, 2020 | 65 | 2020 |
| Structures of endocrine-disrupting chemicals determine binding to and activation of the estrogen receptor α and androgen receptor H Tan, X Wang, H Hong, E Benfenati, JP Giesy, GC Gini, R Kusko, ... Environmental Science & Technology 54 (18), 11424-11433, 2020 | 45 | 2020 |
| Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice M Garcia-Miralles, M Geva, JY Tan, NABM Yusof, Y Cha, R Kusko, LJ Tan, ... JCI insight 2 (23), 2017 | 44 | 2017 |
| Premature expression of a muscle fibrosis axis in chronic HIV infection RL Kusko, C Banerjee, KK Long, A Darcy, J Otis, P Sebastiani, S Melov, ... Skeletal muscle 2, 1-12, 2012 | 43 | 2012 |
| Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing LT Fang, B Zhu, Y Zhao, W Chen, Z Yang, L Kerrigan, K Langenbach, ... Nature biotechnology 39 (9), 1151-1160, 2021 | 42 | 2021 |
| Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse R Kusko, J Dreymann, J Ross, Y Cha, R Escalante-Chong, ... Molecular Neurodegeneration 13, 1-15, 2018 | 36 | 2018 |
| The international MAQC Society launches to enhance reproducibility of high-throughput technologies L Shi, R Kusko, RD Wolfinger, B Haibe-Kains, M Fischer, SA Sansone, ... Nature biotechnology 35 (12), 1127-1128, 2017 | 34 | 2017 |
| A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis CJ Ross, F Towfic, J Shankar, D Laifenfeld, M Thoma, M Davis, B Weiner, ... Genome medicine 9, 1-15, 2017 | 33 | 2017 |
Yoonjeong ChaMITVerified email at mit.edu
